3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3)

Background and Aims: Intra-plaque angiogenesis (IP), present in advanced human atherosclerotic plaques, promotes unstable vascular disease and contributes to increased risk of myocardial infarction and stroke. Because proliferating endothelial cells (ECs) rely on glycolysis for up to 85% of their energy demand, glycolysis inhibition may represent a novel strategy to prevent IP neovascularization, thereby promoting plaque stabilization. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3) is a key enzyme of the glycolysis pathway and plays an essential role in angiogenesis.

Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: B. Emini Veseli, P. Perrotta, A. Abdali, P. Van Wielendaele, G. Monaco, A.-M. Lambeir, M.L. Gelmi, G. Bultynck, W. Martinet, G. De Meyer Source Type: research